Bristol-Myers Squibb Company, Gilead Sciences, Inc. and Merck & Co., Inc. have announced that they are in discussions on the development of a once-daily, fixed-dose combination of three anti-HIV dtext editorEmerging Infectious Diseases
Antiretroviral therapy is highly effective in suppressing human immunodeficiency virus (HIV)1. However, eradication of the virus in individuals with HIV has not been possible to date2. Given that HIV suppression requires life-long antiretroviral therapy, predominantly on a daily basis, there is a ne...
New classes of anti-HIV drugs -- and new drugs in existing classes -- represent the best hope for people with HIV, especially those who have exhausted current therapies. Even people whose HIV is resistant to drugs in all three existing classes stand to benefit from new agents now in the p...
Williams, a partner at Proskauer Rose in Los Angeles, jumped into a $3.6 billion antitrust trial against the makers of two HIV drugs. After lead attorney Kirkland & Ellis partner James Hurst retired three months prior to trial, Williams joined the defense team for Gil...
Fig. 11. Chemical structures of anti-viral drugs used for the treatments of SARS-CoV-2. 3.3. Remdesevir Remdesivir, developed by Gilead Sciences, is a member of antiviral drugs with broad-spectrum (Fig. 10). It was used for RNA virus infections treatments by acting adenosine nucleotide anal...
HIV-1 infection remains a public health problem with no cure. Anti-retroviral therapy (ART) is effective but requires lifelong drug administration owing to a stable reservoir of latent proviruses integrated into the genome of CD4+ T cells1. Immunotherapy
To study the dynamics of wild-type and drug-resistant HIV-1 RT variants, we developed a methodology that follows the fates of individual genomes over time within the viral quasispecies. Single genome sequences were obtained from 3 pigtail macaques infected with a recombinant simian immunodeficiency ...
F-ddA exhibits synergistic antiviral effects when used in combination with other major classes of anti-HIV drugs, including nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors. It is especially useful in combination therapy involving nonnucleoside...
2. REVERSE TRANSCRIPTASE INHIBITORS (RTIS): DISCOVERY OF THE FIRST HIV-1/AIDS DRUGS 3. PROTEASE INHIBITORS (PIS): ADVENT OF COMBINATION ANTIRETROVIRAL THERAPY (CART) 4. DEVELOPMENT OF INTEGRASE STRAND TRANSFER INHIBITORS (INSTIS): KEY DRUGS OF CURRENT CART REGIMENS 5. HIV-1 ENTRY INHIBITORS (...
HIV entry inhibitors are a class of anti HIV drugs that work by preventing HIV from entering susceptible cells in the body. In generally, it is preferred that the HIV entry inhibitor (1) block virus entry into susceptible cells by preventing HIV-1 binding to the cellular receptor CD4, the ...